Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05528783

Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance

Colorectal cancer (CRC) is a common cancer that threatens human health, with the incidence ranking the third in the world. 70% of patients are in the middle and late stages whendiagnosed, and even after radical surgery, 30% - 50% of patients with CRC have recurrence or metastasis after radical surgery. Therefore, after radical surgery and adjuvant chemotherapy, regular monitoring of CRC patients should be paid attention to in order to detect the recurrence and metastasis lesions that can be resected and the early non-invasive metachronous multiple primary tumors.

The sensitivity of FIT-DNA to CRC was 95.5%, the sensitivity to advanced adenoma (AA) was 63.5%, and the specificity was 87.5%, showing a good ability to screen colorectal cancer and precancerous lesions.

At present, there is no report on the application of FIT-DNA combined detection technology in the high-risk recurrence period and mid - and long-term monitoring after CRC surgery in China. In this study, Fit-DNA combined detection technology was applied to the follow-up monitoring of patients after CRC surgery, so as to optimize the current typical postoperative follow-up strategy, find early recurrence and multiple primary colorectal tumors after CRC surgery, seek the best postoperative follow-up model, improve the compliance of patients to follow-up, and ultimately benefit survival.

Detailed Description:Outline:This study was a single-center, observational study. Fit-DNA detection technology was used as a target method, and colonoscopy was used as the gold standard control to follow up and monitor patients with colorectal tumors after surgery, and to explore whether it is an effective non-invasive auxiliary method for monitoring CRC recurrence and metastasis and multiple primary colorectal tumors.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Colorectal Department,SunYat-sen University Cancer Center

Guangzhou, Guangdong, 510062, China

Location status: Recruiting

Location contact

Junzhong lin, PhD

CONTACT

[email protected]

+86-13802446666

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1). The pathological diagnosis was colorectal adenocarcinoma; 2). Age: 18 to 80 years old,allgenders; 3). Radical surgery for CRC is required; 4). No preoperative antitumor therapy (including chemotherapy, radiation therapy, targeted therapy, and immunotherapy); 5). Preoperative examination revealed no distant metastasis; 6). There were no severe hemorrhoids or other known conditions that can cause gastrointestinal bleeding before surgery; 7). The clinical treatment data were complete;

Exclusion criteria

  • 1). With a history of digestive tract tumors other than CRC; 2). Previous colorectal surgery; 3). Patients requiring a fistula; 4). With complete intestinal obstruction or perforation; 5). Women who are pregnant or breastfeeding; 6). Patients with metastases found in other sites during surgery that cannot be removed radically; 7). Patients unwilling or unable to sign an informed consent form; 8). A strict vegetarian; 9). Patients who are unwilling to follow up according to the protocol or have poor follow-up compliance; 10). Any conditions that the study physician deemed inappropriate for inclusion。

Exit or terminate criteria:

  • . Follow-up information for the patients was not available
  • . Distant metastasis was diagnosed after surgery
  • . Subjects died before the end of follow-up.

Treatment and study plan

Primary outcomes

  1. The diagnostic sensitivity and specificity of FIT-DNA detection for local recurrence and advanced colorectal neoplasm of CRC.

    Time frame: up to 5 years

    The diagnostic sensitivity and specificity of FIT-DNA detection for local recurrence and advanced colorectal neoplasm of CRC.

Secondary outcomes

  1. 1.The AUC of FIT-DNA in recurrent CRC and advanced colorectal stage.

    Time frame: up to 5 years

    1.The AUC of FIT-DNA in recurrent CRC and advanced colorectal stage.

  2. 2.NPV、PPVof FIT-DNA in recurrent CRC and advanced colorectal stage.

    Time frame: up to 5 years

    2.NPV、PPVof FIT-DNA in recurrent CRC and advanced colorectal stage.

  3. 3.The time interval between CRC recurrence and advanced colorectal neogenesis after the first positive appearance was detected by FIT-DNA detection.

    Time frame: up to 5 years

    3.The time interval between CRC recurrence and advanced colorectal neogenesis after the first positive appearance was detected by FIT-DNA detection.

Study contacts

Contact information is provided by the study sponsor or research team.

Junzhong Lin

CONTACT

[email protected]

+86-13802446666

Zhizhong Pan

CONTACT

[email protected]

+86-13719388166

Sponsors and collaborators

Lead sponsor

Sun Yat-sen University

Other

Collaborators

  • New Horizon Health

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2027
First posted
Sep 6, 2022
Registry last updated
Sep 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.